When a Superficial Risk Assessment Leads to Disaster

by Marco Arezio

The 2018 acquisition of Monsanto by Bayer, a $63 billion cash deal, has become a textbook example of how a strategic decision can turn into a financial nightmare.

Despite Bayer’s attempt to bury the Monsanto name, the economic and legal implications tied to the acquisition have proven especially burdensome for the German chemical-pharmaceutical giant.

The Gamble and Burden of Roundup

When Bayer decided to acquire Monsanto, its goal was to bolster its agricultural division by gaining near-complete control over genetically modified seeds and the world’s most controversial herbicide: Roundup, which is glyphosate-based.

This product was already widely criticized and faced multiple lawsuits for its alleged carcinogenic effects, particularly in the United States.

Despite the evident risks, Bayer appeared to be betting on a strategy that would transform it into an undisputed giant in agritech.

However, reality turned out to be very different. The legal disputes in America began to multiply shortly after the acquisition, forcing Bayer to face massive legal costs and compensations that eroded profits and slashed the company's market value.

According to Bloomberg, by 2023, Bayer had paid around $10 billion in settlements to resolve thousands of glyphosate-related lawsuits.

Further reports from CNBC indicated that as of 2024, there are still over 30,000 pending cases, suggesting the issue is far from resolved.

Stock Market Plunge and Reduced Capital

The consequences have been clearly visible in the group’s recent stock market crisis. Bayer’s shares fell by 14.5%, reaching €20.88 at the end of October 2024.

This represents one of the worst performances among companies in Germany’s DAX index and the Stoxx Europe 600.

In a year, Bayer’s stock value dropped by 48%, with a market capitalization now at €20.51 billion—less than a third of the $63 billion paid for Monsanto’s acquisition.

According to Reuters, Bayer’s stock performance suffered not only due to legal issues but also disappointing results in the agricultural division amid growing competition in the seed and pesticide sectors.

Regulatory pressure, especially in Europe, has made it challenging for Bayer to keep its growth promises.

Additionally, the Wall Street Journal reported that Bayer’s sales of pesticides and genetically modified seeds have fallen short of expectations due to the increasing number of legal restrictions, particularly in crucial markets like the European Union.

This situation brings to light two major problems for the German giant: on one hand, a collapse in investor confidence, who now see the Monsanto acquisition as one of the worst strategic blunders in Bayer’s history; on the other, persistent difficulties within the agricultural division, in which Bayer invested heavily but has failed to achieve the desired outcomes.

The Impact on Agritech and Bayer’s Future

The struggles within the agritech division, coupled with legal challenges, have also forced Bayer to revise its 2024 profit forecast, lowering it to a range between €10.4 and €10.7 billion.

This is a strong indication of the internal issues the company is facing, with the need to manage a substantial debt while facing increasing pressure from competitors.

In this scenario, new CEO Bill Anderson has a particularly challenging task: attempting to reverse the trend, relaunch the company, and manage the legal burden inherited from the acquisition.

According to the Financial Times, Anderson has announced a restructuring plan aimed at reducing costs and focusing on Bayer’s core activities, such as the pharmaceutical sector, hinting at a possible reduction in exposure to agritech.

Confirming this direction, the CEO told Bloomberg he is open to evaluating strategic partnerships and joint ventures that could ease the burden of certain divisions, with the goal of improving operational efficiency and resolving part of the financial issues.

Trust in Bayer, a historic German company founded in 1863 and famous for inventing aspirin, is now at an all-time low, and the market seems to be demanding a radical change of direction.

Furthermore, the R&D activities of the pharmaceutical division, which were once a source of stability, are now facing significant challenges due to the competition from new players in the biotechnology sector.

According to an article in Nature, Bayer is attempting to recover by increasing investments in new pharmaceutical technologies, including advanced genetic treatments, but results will not be immediate.

A Management Lesson

In hindsight, the Monsanto acquisition can be considered one of the most serious strategic errors in the company’s history.

This experience represents a significant lesson for the management world: a superficial assessment of legal risks and an underestimation of the social and environmental context can turn a potential opportunity into a financial disaster.

According to analysts at Deutsche Bank, Bayer now needs to focus on a debt reduction strategy and a reorganization of non-strategic activities to regain stability.

Investors are demanding concrete actions, including a possible divestiture of non-essential assets, to streamline the corporate structure and reduce legal exposure.

In a recent report by Goldman Sachs, it was suggested that Bayer could improve its financial position by partially divesting its Material Science division, thereby freeing up capital for key sectors.

Despite everything, Bayer’s future is not yet written. The management’s ability to address internal issues with clarity and to propose a clear and sustainable vision for the future will be decisive.

But one thing is certain: the ghost of Monsanto will continue to haunt Bayer for a long time, testing its capacity to rise from its own ashes.

© Reproduction Prohibited